19 completed. 19 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 19 |
| Phase 2 | 1 | Completed 1 |
Follow Metastatic Solid Tumors: new trials by email Literature Review of Metastatic Solid Tumors trials Research Report on Metastatic Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors JSKN003 - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Completed | Alphamab (Australia) Co Pty Ltd. | 62 | 2022-09-02 | 2025-08-22 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors GDC-1971, Atezolizumab, Omeprazole - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Completed | Genentech, Inc. | 57 | 2022-08-17 | 2025-07-03 |
| M1231 in Participants With Solid Tumors M1231 - Metastatic Solid Tumors, Esophageal Cancer | Phase 1 | Completed | EMD Serono Research & Development Institute, Inc. | 23 | 2021-01-13 | 2023-07-07 |
| First in Human Study of M6223 M6223, Bintrafusp alfa - Metastatic Solid Tumors | Phase 1 | Completed | EMD Serono Research & Development Institute, Inc. | 58 | 2020-07-10 | 2026-05-04 |
| A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors Retifanlimab, INCB001158, Retifanlimab + INCB001158 - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Completed | Incyte Biosciences Japan GK | 18 | 2019-07-22 | 2022-02-25 |
| Phase I/Ib Multiple Ascending Dose Study in China Avelumab 3 mg/kg Q2W, Avelumab 10 mg/kg Q2W, Avelumab 20 mg/kg Q2W - Metastatic Solid Tumors | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 24 | 2018-04-24 | 2024-02-23 |
| Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers rhIL-15, Ipilimumab, Nivolumab - Metastatic Solid Tumors, Treatment-Refractory Cancers | Phase 1 | Completed | National Cancer Institute (NCI) | 31 | 2018-02-05 | 2025-12-18 |
| A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors retifanlimab - Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Completed | Incyte Corporation | 325 | 2016-11-15 | 2025-08-03 |
| Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors Mogamulizumab (KW-0761) - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 17 | 2014-10-01 | 2021-04-23 |
| Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors aldoxorubicin, gemcitabine - Metastatic Solid Tumors | Phase 1 | Completed | ImmunityBio, Inc. | 30 | 2014-08-01 | 2022-02-10 |
| Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. Entrectinib - Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Completed | Hoffmann-La Roche | 84 | 2014-07-28 | 2021-06-09 |
| A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety NKTR-102 - Advanced Cancer, Metastatic Solid Tumors | Phase 1 | Completed | Nektar Therapeutics | 33 | 2014-02-01 | 2016-12-22 |
| Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors VCN-01, Gemcitabine, Abraxane® - Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Completed | Theriva Biologics SL | 42 | 2014-01-01 | 2020-10-08 |
| Phase 1b Trial of BGJ398/BYL719 in Solid Tumors BGJ398, BYL719 - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 62 | 2013-10-01 | 2020-12-09 |
| Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors PZP115891, PCI-24781 - Metastatic Solid Tumors | Phase 1 | Completed | Pamela Munster | 90 | 2012-06-25 | 2025-03-21 |
| Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer TAK-117 - Metastatic Solid Tumors | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 125 | 2011-10-01 | 2017-03-09 |
| Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors BMS-754807, Paclitaxel, Carboplatin - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Completed | Bristol-Myers Squibb | 21 | 2009-04-01 | 2012-07-13 |
| Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors AT13387 - Metastatic Solid Tumors | Phase 1 | Completed | Astex Pharmaceuticals, Inc. | 62 | 2008-05-01 | 2024-08-02 |
| Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002) MK-2206 - Locally Advanced Tumors, Metastatic Solid Tumors | Phase 1 | Completed | Merck Sharp & Dohme LLC | 104 | 2008-04-15 | 2019-04-01 |
Neoplasms (4) · Neoplasm Metastasis (3) · Acrocephalosyndactylia (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Disease Progression (1) · Esophageal Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Pancreatic Neoplasms (1) · Sarcoma (1)
Neoplasms (4) · Neoplasms by Site (3) · Neoplastic Processes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Bone Diseases (1) · Bone Diseases, Developmental (1) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Craniofacial Abnormalities (1)
Gemcitabine (2) · (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone (1) · Albumin-Bound Paclitaxel (1) · Alpelisib (1) · BMS 181339 (1) · BMS 754807 (1) · Carboplatin (1) · DOXO-EMCH (1) · Echocardiography (1) · Electrocardiography (1) · Ipilimumab (1) · MK 2206 (1) · Nivolumab (1) · Omeprazole (1) · Paclitaxel (1)
EMD Serono Research & Development Institute, Inc. (2) · Alphamab (Australia) Co Pty Ltd. (1) · Astex Pharmaceuticals, Inc. (1) · Bristol-Myers Squibb (1) · Genentech, Inc. (1) · Hoffmann-La Roche (1) · ImmunityBio, Inc. (1) · Incyte Biosciences Japan GK (1) · Incyte Corporation (1) · Memorial Sloan Kettering Cancer Center (1) · Merck KGaA, Darmstadt, Germany (1) · Merck Sharp & Dohme LLC (1) · Millennium Pharmaceuticals, Inc. (1) · National Cancer Institute (NCI) (1) · Nektar Therapeutics (1)
United States (12) · Australia (5) · Canada (5) · South Korea (4) · Spain (4) · Belgium (2) · China (2) · France (2) · Germany (2) · Italy (2) · New Zealand (2) · United Kingdom (2) · Argentina (1) · Brazil (1) · Bulgaria (1)
Arlene Chan (1) · Dan Levitt, M.D. (1) · Eiji Ueda, MD, PhD, MBA (1) · Ivan Gergel, MD (1) · Jedd Wolchok, MD, PhD (1) · Jibran Ahmed, M.D. (1) · Pamela Munster, MD (1)
PMID 22025163, PMID 25239610, PMID 26565381, PMID 26884591, PMID 31838007, PMID 31838015, PMID 32508818, PMID 33646820, PMID 34427452, PMID 35338084, PMID 35354274, PMID 39509670, PMID 39549678, PMID 39929671
2017 (1)